First patient enrolled in Stimuvax Phase III clinical trial in patients with non-small cell lung cancer

Biomira Inc. (NASDAQ:BIOM) (TSX: BRA) announced that the first patient has been enrolled in the global Phase III clinical trial, START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the efficacy and safety of Stimuvax(R) (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). The trial is being conducted by Merck KGaA of Darmstadt, Germany, ("Merck") and its U.S. affiliate EMD Pharmaceuticals, Inc. pursuant to the terms of a collaboration between Biomira and Merck. The collaboration arrangement provides that Biomira is entitled to receive a milestone payment from Merck upon enrollment of the first...

Want to see the full article?

• Purchase this article for only $3.00